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T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive subtype of chronic lymphocytic leukemia. Usually it
presents in older people with a median age of 61 years. T-PLL is characterized by elevated white blood cell (WBC)
count with anemia and thrombocytopenia, hepatosplenomegaly, and lymphadenopathy; less common findings are
skin infiltration and pleural effusions. The most frequent chromosomal abnormalities in T-PLL include 14q11.2,
chromosome 8, and 11q rearrangements. Also deletions in the short arm of a chromosome 9 are reported in ~30%
of T-PLL together with other aberrations. Here we report a childhood T-PLL case with a de novo del(9)(p13) as sole
acquired anomaly leading to monosomy of the tumor suppressor gene CDKN2A (cyclin-dependent kinase inhibitor 2A).
Also, to the best of our knowledge this is the first case of a childhood T-PLL with this aberration.
Keywords: Childhood T-cell prolymphocytic leukemia (T-PLL), Chromosomal aberrations, Fluorescence in situ
hybridization (FISH), Multicolor banding (MCB)Introduction
T-cell prolymphocytic leukemia (T-PLL) is an aggressive
lymphoproliferative disorder that represents in 2% of all
mature lymphocytic leukemias in adults; also it has been
classified as an aggressive subtype of chronic lympho-
cytic leukemia (CLL) [1]. T-PLL causes major problems
due to negative effects on the immune system, thus pre-
disposing the affected patient to a variety of infections,
and possibly death [2]. T-PLL affects mainly adults (me-
dian age 61 years) and is more common in male (male/
female =2:1) [3].
T-PLL characterized by several clinical features like
splenomegaly (75% of patients), generalized lymphadenop-
athy (50%), and skin infiltration (25%) with skin nodules,
maculopapular rash, or more rarely erythroderma. Also
serous effusions, particularly pleural effusions (15%) are
regularly seen [4,5]. The majority of T-PLL patients present
with severely increased lymphocyte count (>100,000/μl).
Anemia and thrombocytopenia are present in half of
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unless otherwise stated.are usually elevated [6]. The clinical course of the disease is
usually aggressive, with poor or no response to therapy [7].
The immunophenotype of T-PLL cells resembles that
of mature post-thymic T-cells with expression of CD2,
CD3, and CD7. The T-cell receptor (TCR) beta/gamma
genes can be clonally rearranged [1]. The most frequent
chromosomal abnormalities in T-PLL include 14q11.2-
aberrations, chromosome 8 rearrangements and/or 11q
abnormalities, the latter leading to the deletion of the
ataxia-telangiectasia mutated (ATM) and mixed lineage
leukemia (MLL) genes, as well as abnormalities e.g. in
5q, 6q, 9p, 12p, and 13q [8-11].
Here we report an untreated childhood T-PLL case with
do novo del(9)(p13) as sole abnormality, which leads to
monoallely of tumor suppressor gene CDKN2A (cyclin-
dependent kinase inhibitor 2A).Material and methods
Case report
A 16 year old male patient without significant personal
or familial medical chronically presented with a 1 month
history of dyspnea, fatigue, loss of weight, fever and
pleural effusion in right lung. Pleural fluid examination
revealed an elevated white blood cell (WBC) count of
218.4 × 109/l (70% were lymphocytes and 15% wered. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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On physical examination enlarged liver was suggested
whereas, CT scan and echography of the abdomen re-
vealed normal liver size; several skin nodules (1–2 cm) in
different locations such as neck, mandible and armpit
were detected (data not shown). Routine peripheral blood
test showed WBC count of 70.6 × 109/l (74.6% were lym-
phocytes). The red blood cell (RBC) count was 4.52 × 106/
mm3 with a hemoglobin level of 11.8 g/dl and platelets
count of 0.277 × 109/l. Biochemistry analyses revealed
LDH level of 1,377 U/l; alanine aminotransferase (ALT)
level was 142 U/l (normal up to 40U/l); aspartate amino-
trasferase (AST) level 51 U/l (normal up to 40U/l); total
serum protein 6 g/dl (normal 6.4-8.3 g/dl); serum albumin
4 g/dl (normal 3.5-5.2 g/dl); and serum calcium value
9.7 mg/dl (normal 8.5-10.5 mg/dl). Bone marrow smear
showed approximately 95% of cells were blasts. Unfortu-
nately the patient died two months after diagnosis from
the disease due to respiratory arrest.
Cytogenetic analysis
Cytogenetic analysis using GTG-banding was performed
according to standard procedures [12]. A minimum of 20
metaphase cells derived from unstimulated bone marrow
culture were analyzed. Karyotypes were described accord-
ing to the International System for Human Cytogenetic
Nomenclature (ISCN 2009).Figure 1 GTG-banding revealed a deletion of the short arm of a deriv
by arrowhead.Molecular cytogenetics
FISH using a whole chromosome painting (WCP) probe
for chromosome 9 (MetaSystems/Germany) and a locus
specific probe for CDKN2A gene (LSI p16 in 9p21) with a
probe for centromere 9 (Abbott Molecular/Vysis, Abbott
Park, IL, USA) were applied according to manufacturer’s
instructions [12]. Also a multicolor banding probe (MCB)
sets based on microdissection derived region-specific li-
braries for chromosome 9 was applied as previously de-
scribed [13]. A minimum of 20 metaphase spreads were
analyzed, using a fluorescence microscope (AxioImager.
Z1 mot, Carl Zeiss Ltd., Hertfordshir, UK) equipped with
appropriate filter sets to discriminate between a max-
imum of five fluorochromes plus the counterstain DAPI
(4',6- diamino-2-phenylindole). Image capture and pro-
cessing were performed using an ISIS imaging system
(MetaSystems).
Flow cytometry
Flow cytometry of leukemic blasts was performed using
a general panel of fluorescent antibodies against the fol-
lowing antigens typical for different cell lineages and cell
types: CD1a, CD2, CD3, CD4, CD5, CD8, CD10, CD11b,
CD11c, CD13, CD14, CD15, CD16, CD19, CD20, CD22,
CD23, CD32, CD33, CD34, CD38, CD41a, CD45, CD56,
CD57, CD64, CD103, CD117, CD123, CD209, CD235a
and CD243; in addition antibodies against Kappa andative chromosome 9 del(9)(p?). A derivative chromosome is marker
Figure 2 Karyotype and chromosomal aberrations were
confirmed using molecular cytogenetic approaches. (A)
The deletion of CDKN2A was identified on the der(9). (B) The
application of MCB 9 characterized the del(9)(p13) comprehensively.
Abbreviations: # = chromosome; der = derivative chromosome.
Wafa et al. Experimental Hematology & Oncology 2014, 3:28 Page 3 of 5
http://www.ehoonline.org/content/3/1/28Lambda light Chains, sIgD, sIgM, and HLADr were ap-
plied (BD Biosciences). Four-color immunophenotyping
on peripheral blood specimen was performed. Samples
were stained and analyzed on a BD FACSCalibur™ flow
cytometer according to BD Biosciences manuals and
products insert sheets. Autofluorescence, viability, and
isotype controls were included. Flow cytometric data ac-
quisition and analysis were conducted by BD Cellquest™
Pro software.
Results
Karyotyping was performed before initiation of any treat-
ment and GTG banding revealed a karyotype of 46,XY,del
(9)(p?) (20) (Figure 1). Dual color FISH was performed to
confirm presence of the aberration. A probe specific for
CDKN2A confirmed that the deletion encompassed sub-
band 9p21 (Figure 2A). Finally, MCB9 probe set (Figure 2B)
revealed the following karyotype: 46,XY,del(9)(p13) (20).Figure 3 Flow cytometric dot plots showing the abnormal population
CD7 coexpression.Flow cytometric analysis of bone marrow specimen
characterized this case as a T-PLL (Figures 3A-C). The ab-
normal cell population (97% of tested cells) was positive
for CD45, CD2, CD4, CD7, and expressed CD5 heteroge-
neously and at low levels. Also the population was nega-
tive for TdT, CD1a, CD3, CD8, CD34, and HLA-DR.
Discussion
T-PLL primarily affects older adults (median age at pres-
entation, 61 years) with male predominance [3] and is
considered as an aggressive leukemia with poor or no re-
sponse to therapy [7].
T-cell CLL is now reclassified as T-PLL according to
the WHO/revised form of European-American Classifi-
cation of lymphoid neoplasm classification for lymphoid
malignancies because of aggressive clinical behavior [14].
T-PLL represents approximately 2% of all mature lympho-
cytic leukemia in adults and 3% of T-cell malignancies
overall [1,15].
Concerning the immunophenotype of the present case,
it fits into the known picture of T-PLL. Immunpheno-
type of T-prolymphocytes is consistent with that of a
mature post-thymic T-cell. As such it was negative for
CD1a and TdT, but positive for pan T-cell markers, such
as CD2, CD3, CD5, and CD7. CD7 is expressed with
stronger intensity than seen in normal T-cells and other
mature T-cell malignancies, but at levels comparable to
those seen in T-acute lymphocytic leukemia (T-ALL) [16].
Most of the cases (65%) have CD4+/CD8- cells, 21% of
cases are CD4+/CD8+, and 13% of cases are CD4-/CD8+
[17]. Surface expression of CD3 and TCR-α/ß may not be
detected in up to 20% of cases, but their expression is al-
ways seen in the cytoplasm [16].
As already mentioned T-PLL is a rare entity; here we de-
scribe a childhood T-PLL case with de novo del(9)(p13)
leading to monoallelic deletion of the tumor suppressorof T-cells. (A) dim CD45 expression. (B) CD4 expression. (C) CD2 and
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case is unique in two ways: it is the only one ever seen
with this kind of aberration in a childhood case, and it is
the only one with a del(9)(p13) as the sole aberration (for
comparison see [18]).
The most frequent chromosomal abnormalities in
T-PLL include 14q11.2-aberrations involving TCR-region,
and 11q-rearrangements leading to deletions of ATM or
MLL genes. Other yet reported abnormalities involve vari-
ous chromosomal regions like 5, 6, 8, 9p, 7q, 12p, 13q,
14q, 16q, 17, 21 and 22 [8-11,19,20].
T-PLL occurs in enhanced frequencies in ataxia tel-
angiectasia (AT) families [21]. This observation supports
possible association between ATM mutations and T-PLL.
Accordingly Friedenson [22] described ATM mutations in
44-66% of T-PLL patients.
CDKN2A and CDKN2B are tumor suppressor genes lo-
cated in 9p21. They belong to the family of inhibitors of
cyclin-dependent kinases. CDKN2A gene encodes for the
two proteins p14ARF and p16INK4a, and the CDKN2B gene
for p15 INK4b protein; all three are key regulators of G1
phase cell-cycle arrest and senescence [23]. It has recently
been observed that these genes are inactivated in a wide
range of human cancers by epigenetic mechanisms [23,24],
Loss of heterozygosity of chromosome arm 9p, includ-
ing the CDKN2A locus, is one of the most frequent gen-
etic events in childhood ALL, suggesting inactivation of
the second allele or, possibly, haploinsufficiency [25]. Hap-
loinsufficiency of a tumor suppressor gene (e.g. CDKN2A),
has been shown to be adequate to promote tumor pro-
gression [26]. Homozygous deletion of CDKN2A has been
suggested as the dominant mechanism of its inactivation
in leukemogenesis [27].
FOXA1 is a key transcription (TF) factor for CDKN2A
expression [24,28] and a member of fork head gene fam-
ily. TFs have remarkable pioneering activities to open
chromatin for its subsequent cooperation with DNA-
interacting proteins, especially important during em-
bryogenesis and organ development [29,30].
Our case fulfills the clinical, cytogenetic, molecular cyto-
genetic and flow cytometry criteria for a T-PLL case. It is
important to recognize T-PLL because it has a more aggres-
sive clinical course than mature T-cell leukemia. As del(9)
(p13) was the only cytogenetic aberration in this aggressive
childhood T-PLL case alterations of CDKN2A gene may be
an early or even the primary event in T-PLL formation.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
AW provided the case and/or did primary cytogenetic and main part of the
FISH-tests; AA did the flow cytometry analysis; TL, MAKO and AE did detailed
FISH studies. WA supervised the cytogenetic analysis as Director of the MBBD
HGD. AW and TL drafted the paper and all authors read and approved the
final manuscript.Acknowledgments
We would like to thank Prof. Ibrahim Othman, the Director General of
Atomic Energy Commission of Syria (AECS), and Dr. Nizar MirAli, Head of
Molecular Biology and Biotechnology Department, for their support. This
work was supported by the AECS, in parts by the DAAD and KAAD.
Author details
1Human Genetics Division, Department of Molecular Biology and
Biotechnology, Atomic Energy Commission of Syria, P.O. Box 6091,
Damascus, Syria. 2Molecular Biology and Biotechnology Department,
Mammalians Biology Division, Flow-cytometry Laboratory, Atomic Energy
Commission of Syria, P.O. Box 6091, Damascus, Syria. 3Jena University
Hospital, Institute of Human Genetics, Kollegiengasse 10, Jena D-07743,
Germany.
Received: 2 October 2014 Accepted: 12 November 2014
Published: 25 November 2014References
1. Maljaei SH, Brito-Babapulle V, Hiorns LR, Catovsky D: Abnormalities of
chromosomes 8, 11, 14, and X in T-prolymphocytic leukemia studied
by fluorescence in situ hybridization. Cancer Genet Cytogenet 1998,
103:110–116.
2. Oliveira F, Tone LG, Simones BP, Rego EM, Marinato AF, Jacomo RH, Falcao RP:
Translocations t(X;14)(q28;q11) and t(Y;14)(q12;q11) in T-cell prolymphocytic
leukemia. Int J Lab Hematol 2008, 31:453–456.
3. Dearden C: How I treat prolymphocytic leukemia. Blood 2012, 120:538–551.
4. Matutes E, Brito-Babapulle V, Yullie MR, Catovsky D: Prolymphocytic
leukemia of B- and T-cell types. In Chronic Lymphoid Leukemias. Edited by
Cheson BD. New York, Basel: Marcel Dekker, Inc; 2001:525–541.
5. Catovsky D, Ralfkiaer E, Muller-Hermelink HK: T-cell prolymphocytic leukaemia.
In World Health Organization Classification of Tumours: Tumours of Haematopoietic
and Lymphoid Tissues. Edited by Jaffe ES, Harris NL, Stein H, Vardiman JW. Lyon:
IARC Press; 2001:195–196.
6. Pawson R, Schulz TF, Matutes E, Catovsky D: The human T-cell lymphotropic
viruses type 1/11 are not involved in T Prolymphocytic leukaemia and large
granular lymphocytic leukaemia. Leukemia 1997, 11:1305–1311.
7. Brito-Bapapelle V, Pomfret M, Matutes E, Catovsky D: Cytogenetic studies
on prolymphocytic leukemia. II. T-cell pro-lymphocytic leukemia.
Blood 1987, 70:926–931.
8. Durig J, Bug S, Klein-Hitpass L, Boes T, Jons T, Subero-Martin JI, Harder L,
Baudis M, Duhrsen U, Siebert R: Combined single nucleotide
polymorphism-based genomics mapping and global gene expression
profiling identifies novel chromosomal imbalances, mechanisms and
candidate genes important in the pathogenesis of T-Cell prolymphocytic
leukemia with inv(14)(q11q32). Leukemia 2007, 21:2153–2163.
9. Nowak D, Stern MH, Kawamata N, Akagi T, Dyer M, Hofmann WK, Ogawa S:
Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with
high density single nucleotide polymorphism arrays identifies novel
common genomic lesions and acquired uniparental disomy.
Haematologica 2009, 94:518–527.
10. Das D, Pathan S, Joneja M, Al-Musawi F, John B, Mirza K: T-Cell Prolymphocytic
Leukemia (T-PLL) with overlapping cytomorphological features with T-CLL
and T-ALL: a case initially diagnosed by fineneedle aspiration cytology and
lmmunocytochemistry. Diagn Cytopathol 2013, 41(4):360–365.
11. Soulier J, Pierron G, Vecchione D, Garand R, Brizard F, Sigaux F, Stern MH,
Aurias A: A complex pattern of recurrent chromosomal losses and gains
in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer 2001,
31(3):248–254.
12. AL-achkar W, Wafa A, Nweder MS: A complex translocation t(5;9;22) in
Philadelphia cells involving the short arm of chromosome 5 in a case of
chronic myelogenous leukemia. J Exp Clin Cancer Res 2007, 26:411–415.
Wafa et al. Experimental Hematology & Oncology 2014, 3:28 Page 5 of 5
http://www.ehoonline.org/content/3/1/2813. Liehr T, Heller A, Starke H, Rubtsov N, Trifonov V, Mrasek K, Weise A,
Kuechler A, Claussen U: Microdissection based high resolution multicolor
banding for all 24 human chromosomes. Int J Mol Med 2002, 9:335–339.
14. Costa D, Queralt R, Aymerich M, Carrio A, Rozman M, Vallespi T, Colomer D,
Nomdedeu B, Montserrat E, Campo E: High levels of chromosomal
imbalances in typical and small-cell variants of T-Cell prolymphocytic
leukemia. Cancer Genet Cytogenet 2003, 147(1):36–43.
15. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-
Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY,
Muller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA: A revised
European-American classification of lymphoid neoplasms: a proposal from
the international lymphoma study group. Blood 1994, 84:1361–1392.
16. Bartlett NL, Longo DL: T-small lymphocyte disorders. Semin Hematol 1999,
36:164–170.
17. Ginaldi L, Matutes E, Farahat N, De Martinis M, Morilla R, Catovsky D:
Differential expression of CD3 and CD7 in T-cell malignancies: a
quantitative study by flow cytometry. Br J Haematol 1996, 93:921–927.
18. Matutes E, Brito-Babapulle V, Swansbury J, Ellis J, Morilla R, Dearden C,
Sempere A, Catovsky D: Clinical and laboratory features of 78 cases of
T-prolymphocytic leukemia. Blood 1991, 78:3269–3274.
19. Mitelman F, Johansson B, Mertens F: Mitelman Database of Chromosome
Aberrations in Cancer; 2014. http://cgap.nci.nih.gov/Chromosomes/
Mitelman".
20. Salomon-Nguyen F, Brizard F, Le Coniat M, Radford I, Berger R, Brizard A:
Abnormalities of the short arm of chromosome 12 in T cell
prolymphocytic leukaemia. Leukemia 1998, 12:972–975.
21. Stankovic T, Kidd A, Sutcliffe A, McGuire G, Robinson P, Weber P, Bedenham T,
Bradwell A, Easton D, Lennox G, Haites N, Byrd P, Taylor A: ATM mutations
and pheotypes in ataxia-telangiectasia families in the British isles:
expression of mutant ATM and the risk of leukemia, lymphoma and
breast cancer. Am J Hum Genet 1998, 62:334–335.
22. Friedenson B: The BRCA1/2 pathway prevents hematologic cancers in
addition to breast and ovarian cancers. BMC Cancer 2007, 7:152.
23. Collado M, Blasco MA, Serrano M: Cellular senescence in cancer and
aging. Cell 2007, 130:223–233.
24. Zhang Y, Tong T: FOXA1 antagonizes EZH2-mediated CDKN2A repression
in carcinogenesis. Biochem Biophys Res Commun 2014, 453:172–178.
25. Irving JA, Bloodworth L, Bown NP, Case MC, Hogarth LA, Hall AG: Loss of
heterozygosity in childhood acute lymphoblastic leukemia detected by
genome-wide microarray single nucleotide polymorphism analysis.
Cancer Res 2005, 65:3053–3058.
26. Chapman EJ, Harnden P, Chambers P, Johnston C, Knowles MA:
Comprehensive analysis of CDKN2A status in microdissected urothelial
cell carcinoma reveals potential haploinsufficiency, a high frequency of
homozygous co-deletion and associations with clinical phenotype.
Clin Cancer Res 2005, 11:5740–5747.
27. Ohnishi H, Kawamura M, Ida K, Sheng XM, Hanada R, Nobori T, Yamamori S,
Hayashi Y: Homozygous deletions of p16/MTS1 gene are frequent but
mutations are infrequent in childhood T-cell acute lymphoblastic
leukemia. Blood 1995, 86:1269–1275.
28. Li Q, Zhang Y, Fu J, Han L, Xue L, Lv C, Wang P, Li G, Tong T: FOXA1
mediates p16(INK4a) activation during cellular senescence. EMBO J 2013,
32:858–873.
29. Jozwik KM, Carroll JS: Pioneer factors in hormone-dependent cancers.
Nat Rev Cancer 2012, 12:381–385.
30. Katoh M, Igarashi M, Fukuda H, Nakagama H, Katoh M: Cancer genetics
andgenomics of human FOX family genes. Cancer Lett 2013, 328:198–206.
doi:10.1186/2162-3619-3-28
Cite this article as: Wafa et al.: Do novo del(9)(p13) in a childhood T-cell
prolymphocytic leukemia as sole abnormality. Experimental Hematology &
Oncology 2014 3:28.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
